Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Jumps 1.1% – What’s Next?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was up 1.1% on Monday. The company traded as high as $3.85 and last traded at $3.78. Approximately 85,688 shares traded hands during trading, a decline of 77% from the average session volume of 367,441 shares. The stock had previously closed at $3.74.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Armata Pharmaceuticals in a report on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $15.00.

Armata Pharmaceuticals Stock Up 2.2%

The stock has a fifty day simple moving average of $4.81 and a 200-day simple moving average of $7.15. The company has a market capitalization of $136.45 million, a P/E ratio of -0.48 and a beta of 1.34.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last posted its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.17. The business had revenue of $2.51 million for the quarter, compared to analyst estimates of $0.40 million. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%. Analysts predict that Armata Pharmaceuticals, Inc. will post 0.5 earnings per share for the current fiscal year.

Institutional Trading of Armata Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Madison Asset Management LLC bought a new stake in Armata Pharmaceuticals during the 1st quarter worth approximately $21,583,000. BlackRock Inc. bought a new position in Armata Pharmaceuticals in the 2nd quarter valued at $3,629,000. 683 Capital Management LLC acquired a new position in Armata Pharmaceuticals in the fourth quarter worth $878,000. Sei Investments Co. acquired a new position in Armata Pharmaceuticals in the first quarter worth $760,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Armata Pharmaceuticals during the second quarter worth $193,000. 3.57% of the stock is owned by institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for serious bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria. Armata’s approach is intended to address drug-resistant infections while limiting disruption to beneficial bacteria.

The company’s pipeline has included inhaled phage products designed to treat chronic respiratory infections caused by Pseudomonas aeruginosa, including infections associated with cystic fibrosis and other structural lung diseases.